Drug
Saizen®
Saizen® is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_3
4
80%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Phase Distribution5 total trials
Phase 3Large-scale testing
4(80.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4
Trials by Phase
Phase 34 (80.0%)
Phase 41 (20.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_4
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
NCT00256126
completedphase_3
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
NCT00249821
completedphase_3
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
NCT01746862
terminatedphase_3
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
NCT01237340
completedphase_3
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
NCT00933686
Clinical Trials (5)
Showing 5 of 5 trials
NCT00256126Phase 4
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
NCT00249821Phase 3
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
NCT01746862Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
NCT01237340Phase 3
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
NCT00933686Phase 3
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5